General Comments / Chat, page-8829

Finally some reason. There seems to be undue panic:

1. Bisantrene still presents an INCREDIBLE opportunity to improve the length and quality of life of those afflicted with cancer - what an amazing opportunity to be a part of the company that brings this solution to market, this is more than just an opportunity to make money, this is peoples lives.

2. No evidence thus far they bisantrene isn't as effective as historically evidenced or as pre-clinically implied.

3. The strategic update appears at a glance that the timeline is extended significantly but a partnership or deal can occur at any time.

4. We will get RC220 shortly, we will commence new AML trials shortly and partnerships or deals will manifest IMO

GLTAH, be kind, remember your why.